Kura to Present First Long-Term Darlifarnib RCC Data at KCRS 2026
KURA has more than doubled off its 52-week low of $5.45.
Summary
Kura Oncology will present the first long-term follow-up data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in advanced renal cell carcinoma at KCRS 2026 on July 24. The data is expected to support darlifarnib's potential to enhance VEGFR-targeted therapy, a widely used approach in RCC. This follows a series of positive clinical updates for darlifarnib across multiple combinations, including adagrasib and 7+3 chemotherapy, building a broader case for its mechanism. A randomized Phase 1b study is ongoing, with a registrational Phase 3 planned for 2028. A virtual investor call on July 27 will provide further context.
At the time of this announcement, KURA was trading at $11.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $968.5M. The 52-week trading range was $5.45 to $12.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.